Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

Cell Cycle

Volumn 10, Issue 14, 2011, Pages 2323-2330

  Thépot, Sylvain ^a,b   Lainey, Elodie ^a,c   Cluzeau, Thomas ^d,e   Sébert, Marie ^a,b   Leroy, Carole ^a,f   Adès, Lionel ^a,b   Tailler, Maximilien ^a,c,f   Galluzzi, Lorenzo ^a,c,f   Baran Marszak, Fanny ^g   Roudot, Hervé ^g   Eclache, Virginie ^g   Gardin, Claude ^b   De Botton, Stéphane ^f   Auberger, Patrick ^d,e   Fenaux, Pierre ^a,b,c   Kroemer, Guido ^a,f,h,i,j   Boehrer, Simone ^a,b  

^a Institut Gustave Roussy   (France)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSERM   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITÉ PARIS 13   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

ATM; ATR; DNMT1; HL 60; MOLM 13; SKM 1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BIM PROTEIN; CD34 ANTIGEN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; HISTONE H2AX; PUMA PROTEIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CD34 SELECTION; CELL CULTURE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL LINE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CYTOFLUOROMETRY; CYTOPLASM; DEPHOSPHORYLATION; DISEASE COURSE; DNA DAMAGE; DNA DAMAGE RESPONSE; FEMALE; GENE TRANSLOCATION; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; KARYOTYPE 45,X; KARYOTYPE 46,XX; KARYOTYPE 46,XY; LEUKEMOGENESIS; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PHOSPHORYLATION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79960456078     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.14.16399     Document Type: Article

References (37)

1. Fenaux P. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. Semin Hematol 2004; 41:6-12. (Pubitemid 38649813)
2. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program 2004; 80-97.
3. Boehrer S, Ades L, Tajeddine N, Hofmann WK, Kriener S, Bug G, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009; 28:2205-18.
4. Ceccaldi R, Briot D, Larghero J, Vasquez N, Dubois d'Enghien C, Chamousset D, et al. Spontaneous abrogation of the GDNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest 2011; 121:184-94.
5. Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, et al. Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res 2009; 69:8652-61.
6. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009; 668:4-10.
7. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249-56. (Pubitemid 36182492)
8. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010; 24:101-22.
9. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23:1895-909.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-32.
11. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol 2008; 20:705-10.
12. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011; 29:516-23.
13. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5:9001.
14. Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, et al. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002; 8:3549-60. (Pubitemid 35340733)
15. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9:297-308. (Pubitemid 351430844)
16. Ferri KF, Kroemer G. Mitochondria - the suicide organelles. Bioessays 2001; 23:111-5. (Pubitemid 32116642)
17. Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 2005; 115:2610-7.
18. Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep 1997; 17:67-76. (Pubitemid 27267593)
19. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 2010; 16:1865-74.
20. Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Ramos F, et al. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res 2009; 33:1706-9.
21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68. (Pubitemid 29165088)
22. Nakagawa T, Matozaki S, Murayama T, Nishimura R, Tsutsumi M, Kawaguchi R, et al. Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 1993; 85:469-76. (Pubitemid 23349047)
23. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10:1201-4.
24. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203:1657-63. (Pubitemid 44036270)
25. Cataldo VD, Cortes J, Quintas-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 2009; 9:875-84.
26. Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31:2349-70.
27. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3:807-17. (Pubitemid 350162080)
28. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23:1019-28.
29. Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL, et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 2008; 7:2139-45. (Pubitemid 352031516)
30. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002; 265:39-47. (Pubitemid 34628803)
31. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093-107.
32. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12:803-13. (Pubitemid 46653289)
33. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, et al. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett 1998; 61:157-63. (Pubitemid 28260991)
34. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181:1661-72.
35. Mouhamad S, Galluzzi L, Zermati Y, Castedo M, Kroemer G. Apaf-1 deficiency causes chromosomal instability. Cell Cycle 2007; 6:3103-7.
36. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, et al. The inositol-1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ 2009; 16:1006-17.
37. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8.